E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020161 |
E.1.2 | Term | HIV infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Part 1: Single Ascending Dose (SAD) Study To evaluate the safety and tolerability of M113V when administered as a single dose during ART Part 2: Multiple Ascending Dose (MAD) Study To evaluate the safety and tolerability of IMC-M113V when administered in a multiple dose schedule, up to at least week 12, in participants receiving ART |
|
E.2.2 | Secondary objectives of the trial |
•To characterise the pharmacokinetic (PK) profile of IMC-M113V in single dose and multiple dose schedules •To evaluate incidence of anti-IMC-M113V antibody formation following single and multiple infusions. •To determine pharmacodynamic (PD) changes in the systemic immune response in relation to treatment with IMC-M113V, including but not limited to changes in peripheral cytokines and lymphocyte counts •To determine the incidence and duration of post-treatment control during analytical therapy interruption in participants completing multiple dose schedules •To determine the recommended Phase 2 dosing regimen
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Participants are eligible to be included in the study only if all of the following criteria apply: Age 1. 18-65 years inclusive, at time of informed consent HLA 2. HLA-A*02:01-positive (central laboratory testing) Weight 3. ≥ 50 kg Condition Under Study and Prior Therapy 4. Documented evidence of HIV-1 infection 5. On continuous ART for a minimum of 12 months and maximum of 7 years at the time of planned first dose 6. Plasma HIV RNA < 50 copies/mL at Screening and at all available determinations in the 12-month period preceding Screening 7. Current CD4+ T cell count > 500 cells/μL 8. CD4+ T cell nadir > 200 cells/μL Contraception 9. Participants who engage in sexual activity which could result in pregnancy for themselves or their partner(s) must agree to use highly effective methods of contraception from the trial Screening date until 3 months after the final dose of the study intervention or longer if required by local regulations; cessation of contraception after this point should be discussed with a responsible physician. Highly effective methods of contraception are described in Section 10.4. a. Participants are not allowed to donate sperm from the time of enrolment until 3 months post-administration of study interventions or longer if required by local regulations. b. Participants must refrain from egg donation during the study. Informed Consent 10. Capable of giving signed informed consent as described in Section 10.1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol. |
|
E.4 | Principal exclusion criteria |
Participants are excluded from the study if any of the following criteria apply: Condition Under Study and Prior/Current Antiretroviral Therapy 1. Known HIV controller: pVL < 2000 copies/mL in absence of ART for at least 12 months and on ≥ 2 determinations. 2. Initiated ART within 12 weeks of a diagnosis of primary HIV infection, confirmed by any of the following: a. Positive HIV-1 serology ≤ 12 weeks after a documented negative HIV-1 antibody (Ab) test, b. Negative HIV Ab test plus either positive p24 antigen (Ag) test or detectable HIV RNA, c. HIV-1 Ab avidity test consistent with recent infection, or d. Weakly reactive or equivocal 4th generation HIV Ab/Ag test. 3. Prior AIDS-defining condition will preclude participation in Part 1 if diagnosed within 90 days prior to Screening. A prior AIDS-defining condition at any time will preclude participation in Part 2. 4. Individuals receiving an ART regimen containing a non-nucleoside reverse transcriptase inhibitor may not enrol in Part 2 unless willing and able to switch to a short-acting alternative prior to receiving their first dose of study drug. Medical Conditions 5. Co-infection with HBV (defined as positive HBsAg test or detectable HBV DNA) or HCV infection (defined as detectable HCV RNA). 6. Current active Mycobacterium tuberculosis infection or known untreated latent infection. 7. History of clinically significant cardiovascular disease or impaired cardiac function, including any of the following: a. Congestive heart failure (New York Heart Association Class ≥3). b. Uncontrolled hypertension (consistent findings of systolic blood pressure [BP] >160 mmHg or diastolic BP >110 mmHg, as defined in Section 8.5.2). c. History of ventricular arrhythmia currently requiring medical treatment or uncontrolled atrial fibrillation. d. QTcF > 470 msec on Screening electrocardiograms (ECGs) or known history of congenital prolonged QT syndrome. e. Acute myocardial infarction or unstable angina pectoris ≤ 6 months prior to Screening. 8. Active autoimmune disease requiring immunosuppressive treatment, including inflammatory bowel disease (ulcerative colitis or Crohn’s disease), within 5 years of screening. 9. Participants with prior solid organ or bone marrow transplant. 10. History of malignant disease will preclude participation if diagnosed in the preceding 2 years from the planned first dose of IMC-M113V; in addition, history of systemic virus-associated cancer, including Kaposi’s sarcoma and lymphoma, will preclude participation in Part 2 if diagnosed at any time. Prior/Concomitant Therapy 11. Pregnant or lactating women. 12. Use of blood products, cytokine therapy or other immunotherapy or immunosuppressive medication in the preceding 3 months from Screening. 13. Current or recent systemic steroid therapy (in the preceding 3 months from screening) or anticipated need for systemic steroids during the study with the following exceptions: a. Treatment for well-controlled and asymptomatic adrenal insufficiency is permitted, but replacement dosing is limited to prednisone ≤ 12 mg daily or the equivalent. b. Local steroid therapies (eg, optic, ophthalmic, intra-articular, or inhaled medications) are acceptable. c. Premedication for allergy to contrast reagent. Prior/Concurrent Clinical Study Experience 14. History of any investigational HIV immunotherapy or vaccine within 6 months of Screening. 15. Planned receipt of vaccines: live vaccines are not permitted within 28 days, and non-live vaccines within 14 days of planned first administration of IMC-M113V. Diagnostic Assessments 16. Participants must not have received prior treatment with an ImmTAC. 17. Participation in other interventional studies is not permitted during the treatment and ATI periods of this study. 18. If any of the following laboratory exclusion criteria are met, then the site may have the participant retested. If a single value is within ±10% of the listed laboratory exclusion criterion value upon retest, and the value is considered not clinically significant by the physician Investigator, the participant may be considered for enrolment: a. Hemoglobin < 120 g/L for participants assigned male at birth; < 110 g/L for participants assigned female at birth b. Platelet count < 150 × 109/L c. Alanine aminotransferase (ALT) > 3 × ULN (upper limit of normal) d. eGFR (Foundation, 2009) < 60 mL/min/1.73 m2 (calculated using CKD-EPI equation, 2009; or measured) Other Exclusions 19. For subjects enrolling in Part 2, inability or unwillingness to adhere to safer sex practices during ART interruption. 20. Known or suspected hypersensitivity or previous severe reactions to any of the constituents of IMC-M113V, or the drugs used in the pre-medication regimen. 21. Any medical condition that would, in the investigator’s judgement, interfere with the patient’s participation in the study due to safety concerns, compliance with study procedures or interpretation of study results. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Incidence and severity of treatment-emergent adverse events (TEAEs) • Incidence of dose-limiting toxicities (DLTs) • Changes in safety laboratory parameters, vital signs, and electrocardiogram (QTcF) • Incidence of serious adverse events (SAEs) and AEs leading to treatment interruption, dose reduction, or discontinuation through 28 days after the last infusion of study treatment |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Incidence rates will be used to summarise primary endpoints relating to the incidence of AEs. The denominators for incidence rate calculations will be the Safety Analysis Set (SAF) for participants in the respective part of the study (Part 1 - SAD and Part 2 -MAD) except for summaries of DLTs, which will be based on the SAD DLT evaluable set and MAD DLT evaluable set. Numerators will generally be based on TEAEs, which are defined as an AE that occurs after the first dose of investigational product and within 28 days of the last dose of investigational product. |
|
E.5.2 | Secondary end point(s) |
•IMC-M113V pharmacokinetics (PK) parameters (eg, AUC, Cmax, Tmax, t1/2) at multiple time points from baseline up to 72 hours post-dose in SAD and MAD (first dose) and after each subsequent dose in MAD studies •Incidence of anti-IMC-M113V antibody formation following administration of one or more doses of study drug. •Change in serum cytokines/chemokines and peripheral blood lymphocyte counts (absolute values and fold-change) from baseline through 72 hours post-dosing with IMC-M113V in SAD and MAD schedules and during Follow-Up •Proportion of participants with pVL < 200 copies/mL 12 weeks after interruption of ART (W24) •Proportion of participants resuming ART before W24 •Duration of post-treatment control (pVL < 200 copies/mL) after interruption of ART •Duration of virological suppression (pVL <1000 copies/mL) afterinterruption of ART •Identification of at least 1 tolerable dosing regimen for further evaluation in subsequent development
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Proportion of participants with pVL < 200 copies/mL 12 weeks after interruption of ART (W24) • Proportion of participants resuming ART before W24 • Duration of post-treatment control (pVL < 200 copies/mL) after interruption of ART • Duration of virological suppression (pVL < 1000 copies/mL) after interruption of ART |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 14 |